Asembia26 wraps today — and the conversations this week confirmed what the most prepared teams already know.
Specialty pharma, market access, and rare disease strategy converged in Las Vegas. The signal was clear: the industry’s next chapter belongs to teams who stopped waiting on incomplete data.
What this week made undeniable
- Rare disease payer access is its own discipline now.
The payer landscape sessions put it plainly: the general market access playbook doesn’t hold in rare disease. Smaller populations. Stricter evidence requirements. Harder questions. The organizations that answer those questions with real, representative, verified patient data won’t just compete — they’ll set the standard.
- AI accountability has arrived — not approaching.
From Optum Rx to URAC, every conversation landed in the same place: AI tools without clinical grounding and transparent governance are on borrowed time. The bar has shifted permanently from “can it work?” to “can you prove it works — safely, at scale, in the populations that matter?”
- Launch excellence in rare disease demands a different foundation entirely.
Jazz Pharmaceuticals and Apellis illustrated it well: teams that win at launch aren’t just moving faster. They’re better informed from day one — with patient-level data that reflects the actual disease, not a billing code approximation of it.
- RWE belongs in the strategy from the start — not the appendix.
Tommy Bramley and Michael Eaddy challenged the industry to stop treating real-world evidence as a post-approval formality. The programs that use RWE as a core commercial asset — built on the patients most pipelines never reach — are the ones defining what good looks like.
In rare disease and oncology, every one of these conversations traces back to the same gap: the distance between the patients in your data and the patients in the real world.
Bridging that gap is exactly what Clinakos has done with Clarion™, Integrated Patient Data™, and Medically Smart AI™
